Thalidomide: A novel template for anticancer drugs

Seminars in Oncology

Volumn 28, Issue 6, 2001, Pages 602-606

  Stirling, D ^a  

^a CELGENE CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; IMMUNOMODULATING AGENT; LENALIDOMIDE; THALIDOMIDE; UNCLASSIFIED DRUG;

CLINICAL TRIAL; CYTOKINE PRODUCTION; DRUG INDUCED DISEASE; DRUG POTENCY; DRUG SAFETY; ERYTHEMA NODOSUM LEPROSUM; HUMAN; HUMAN CELL; LYMPHOCYTE PROLIFERATION; MONONUCLEAR CELL; MULTIPLE MYELOMA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; REVIEW; SINGLE BLIND PROCEDURE; T LYMPHOCYTE;

EID: 0035214909     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0093-7754(01)90032-6     Document Type: Article

References (17)

1. The saga of thalidomide (concluded): Neuropathy to embryopathy, with case reports of congenital anomalies
2. The influence of thalidomide on the clinical and immunologic manifestations of erythema nodosum leprosum
3. Thalomid (thalidomide) capsules: A review of the first 18 months of spontaneous postmarketing adverse event surveillance, including off-label prescribing
4. Thalidomide: Current and potential clinical applications
5. Potential novel uses of thalidomide: Focus on palliative care
6. Thalidomide in multiple myeloma
7. Current role of thalidomide in cancer treatment
8. Antitumor activity of thalidomide in refractory multiple myeloma
9. Thalidomide analogue CC1069 inhibits development of rat adjuvant arthritis
10. Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-α
11. Thalidomide analogs and PDE4 inhibition
12. CC-3052: A water-soluble analog of thalidomide and potent inhibitor of activation-induced TNF-α production
13. Amino-substituted thalidomide analogs: Potent inhibitors of TNF-α production
14. Thalidomide selectively inhibits tumor necrosis factor α production by stimulated human monocytes
15. Inhibition of IL-12 production by thalidomide
16. Differential regulation by thalidomide and dexamethasone of cytokine expression in human peripheral blood mononuclear cells
17. Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset